Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Change in Inventory (2021 - 2025)

Historic Change in Inventory for Ascendis Pharma A (ASND) over the last 5 years, with Q4 2025 value amounting to $583238.9.

  • Ascendis Pharma A's Change in Inventory rose 10180.87% to $583238.9 in Q4 2025 from the same period last year, while for Dec 2025 it was -$44.6 million, marking a year-over-year increase of 5233.43%. This contributed to the annual value of $340.8 million for FY2025, which is 787.52% up from last year.
  • Per Ascendis Pharma A's latest filing, its Change in Inventory stood at $583238.9 for Q4 2025, which was up 10180.87% from $353.1 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Change in Inventory high stood at $353.1 million for Q3 2025, and its period low was -$65.2 million during Q3 2021.
  • In the last 5 years, Ascendis Pharma A's Change in Inventory had a median value of -$19.5 million in 2022 and averaged $20.8 million.
  • Per our database at Business Quant, Ascendis Pharma A's Change in Inventory crashed by 76295.26% in 2023 and then skyrocketed by 235869.41% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Change in Inventory stood at -$23.0 million in 2021, then dropped by 18.25% to -$27.2 million in 2022, then rose by 21.79% to -$21.3 million in 2023, then crashed by 51.37% to -$32.2 million in 2024, then surged by 101.81% to $583238.9 in 2025.
  • Its last three reported values are $583238.9 in Q4 2025, $353.1 million for Q3 2025, and $343.4 million during Q2 2025.